Leerink Partnrs Issues Optimistic Forecast for STOK Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Leerink Partnrs raised their FY2024 earnings per share (EPS) estimates for shares of Stoke Therapeutics in a research note issued on Tuesday, November 5th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings of ($2.00) per share for the year, up from their previous estimate of ($2.05). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.10) per share. Leerink Partnrs also issued estimates for Stoke Therapeutics’ Q4 2024 earnings at ($0.50) EPS, FY2025 earnings at ($2.25) EPS, FY2026 earnings at ($2.60) EPS, FY2027 earnings at ($2.75) EPS and FY2028 earnings at ($2.60) EPS.

A number of other brokerages have also recently commented on STOK. Wedbush reaffirmed an “outperform” rating and issued a $17.00 price target on shares of Stoke Therapeutics in a research note on Thursday, July 11th. Leerink Partners started coverage on Stoke Therapeutics in a research note on Monday, October 14th. They issued an “outperform” rating and a $18.00 price target for the company. Needham & Company LLC reissued a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research note on Wednesday. Finally, HC Wainwright reissued a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Stoke Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $20.83.

Stoke Therapeutics Price Performance

Shares of STOK stock opened at $13.27 on Friday. The stock has a market cap of $698.64 million, a PE ratio of -6.09 and a beta of 0.95. The stock has a 50-day moving average of $13.24 and a 200-day moving average of $13.70. Stoke Therapeutics has a one year low of $3.77 and a one year high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. The company had revenue of $4.89 million during the quarter, compared to analysts’ expectations of $3.46 million. Stoke Therapeutics had a negative return on equity of 57.89% and a negative net margin of 683.35%.

Insider Buying and Selling

In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 1,937,500 shares of the company’s stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the completion of the transaction, the insider now owns 8,906,181 shares of the company’s stock, valued at $125,131,843.05. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 11.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Stoke Therapeutics

A number of large investors have recently bought and sold shares of STOK. Redmile Group LLC boosted its position in Stoke Therapeutics by 93.2% during the 1st quarter. Redmile Group LLC now owns 5,073,049 shares of the company’s stock worth $68,486,000 after acquiring an additional 2,447,543 shares during the last quarter. Lynx1 Capital Management LP boosted its position in Stoke Therapeutics by 40.3% during the 2nd quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock worth $70,052,000 after acquiring an additional 1,488,371 shares during the last quarter. Assenagon Asset Management S.A. acquired a new position in Stoke Therapeutics during the 2nd quarter worth approximately $19,835,000. Baker BROS. Advisors LP boosted its position in Stoke Therapeutics by 65.9% during the 1st quarter. Baker BROS. Advisors LP now owns 3,368,443 shares of the company’s stock worth $45,474,000 after acquiring an additional 1,338,309 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund boosted its position in Stoke Therapeutics by 426.1% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock worth $18,741,000 after acquiring an additional 1,123,500 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.